Australia vs New Zealand: Proportion of isolates with decreased susceptibility or resistance
Australia
0.01
in 2020
New Zealand
0.1
in 2020
Australia rank
12th
New Zealand rank
11th
Proportion of isolates with decreased susceptibility or resistance over time
- Australia
- New Zealand
How they compare
New Zealand currently reports 0.1 against 0.01 in Australia, a difference of 0.09.
That makes New Zealand's figure about 10.0 times Australia's.
The two have swapped places 5 times across 10 shared years of data; in 2009 it was Australia ahead.
Australia ranks 12th and New Zealand ranks 11th of 52 countries.
Across the 3 decades both report, Australia averaged higher in 2 and New Zealand in 1.
Head to head by decade
| Decade | Australia | New Zealand | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0317 | 0 | 0.0317 | Australia |
| 2010s | 0.4418 | 0.3595 | 0.0822 | Australia |
| 2020s | 0.01 | 0.1 | 0.09 | New Zealand |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher proportion of isolates with decreased susceptibility or resistance, Australia or New Zealand?
- New Zealand, at 0.1 against 0.01 in Australia as of 2020.
- What is the difference in proportion of isolates with decreased susceptibility or resistance between Australia and New Zealand?
- 0.09, with New Zealand ahead.
- How many years of comparable data are there for Australia and New Zealand?
- 10 years are reported by both, from 2009 to 2020.
- How do Australia and New Zealand rank globally for proportion of isolates with decreased susceptibility or resistance?
- Australia ranks 12th and New Zealand ranks 11th of 52 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP. Statizoid refreshes it automatically from the source and publishes the full history for both places.